Crossmark

Serum inter-alpha-trypsin inhibitor heavy chain 4 in patients with inflammatory bowel disease: correlation with disease risk, inflammation, activity, and its variation after treatment

Crossref DOI link: https://doi.org/10.1007/s11845-021-02837-3

Published Online: 2021-11-29

Published Print: 2022-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wen, Nuan

Zhao, Na

Xu, Huixian

Zhao, Ying

Ma, Jian http://orcid.org/0000-0001-5032-3826
License Information

Text and Data Mining valid from 2021-11-29

Version of Record valid from 2021-11-29
More Information

Article History

Received: 23 September 2021

Accepted: 22 October 2021

First Online: 29 November 2021

Declarations

:

: The written informed consents were gathered from all subjects. The study was permitted by Institutional Review Board.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below